Sell your addiction treatment center

What buyers evaluate

Substance use treatment carries more regulatory and reputational surface area than most healthcare services, so diligence starts with legitimacy and ends with economics.

Licensure and accreditation

State program licenses, CARF or Joint Commission status, and any conditions attached to them.

Level of care mix

Detox, residential, partial hospitalization, intensive outpatient, outpatient, and MAT each carry different margin and risk.

Payer relationships

In network agreements are valued well above out of network single case arrangements.

Census stability and admissions

Where admissions come from, cost per admission, and length of stay trends.

Marketing and compliance

Patient brokering exposure, call center practices, and lab and toxicology billing history.

Structure and what you keep

Programs with real estate often split the transaction: the operating business sells at a multiple of EBITDA, and the property either sells separately or stays with you under a lease. Owners who want continued upside take rollover equity in the acquiring platform.

Substance Use Disorder (SUD) Market Landscape

The addiction treatment sector continues to see consolidation, particularly in the Comprehensive Treatment Center (CTC) and Opioid Treatment Program (OTP) segments. In October 2024, Acadia Healthcare acquired three opioid treatment centers in South Carolina. Following this, Acadia reported a network of 165 CTC locations across 33 states, serving over 72,000 patients daily. Terms for these specific acquisitions were not disclosed.

Buyers in the SUD space are highly focused on the 'Continuum of Care.' Centers that offer multiple levels of service from medically monitored detox to intensive outpatient (IOP) and sober living, are often more attractive than standalone facilities. This integrated model provides a more stable revenue stream and better patient outcomes, which are key metrics for modern healthcare investors.

Valuation Realities for Treatment Centers

Valuation is significantly impacted by your facility's real estate strategy. Buyers may prefer to purchase the operations and lease the building, or they may want to acquire both. If you own the real estate, ensure the lease you charge the business is at fair market value, as an over-market lease will artificially depress your EBITDA and lower your operational valuation. This is a complex area requiring specialized financial advice.

Payer mix is the second most critical factor. The shift away from out-of-network (OON) reimbursement toward in-network contracts has stabilized valuations but generally at lower multiples than the OON 'gold rush' era. Compliance and UR (Utilization Review) processes are under the microscope; any history of aggressive billing can be a deal-breaker. No private valuation range is an established fact; it depends entirely on your specific metrics.

Compliance and Regulatory Scrutiny

State and federal regulators have increased oversight of the addiction treatment industry. The DOJ and FTC inquiry into healthcare ownership, launched in March 2024, is particularly relevant for centers with private equity backing. During a sale, expect a thorough investigation into your marketing practices, patient referral sources, and laboratory billing. Transparency during this phase is essential for maintaining buyer trust.

Sellers must also consider the tax implications of their deal structure. An asset sale may lead to double taxation in a C-Corp, whereas an S-Corp or LLC might offer more flexibility. This guide does not provide legal or tax advice, and you should consult with professionals before signing any binding documents. A well-prepared seller will organize available historical financials, tax returns, payer contracts, licenses, and compliance records in a controlled data room.